Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results
-- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time --
View HTML
Toggle Summary Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Monday, March 2
SAN DIEGO , Feb. 23, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time ( 2:00 p.m. Pacific Time ) on Monday, March 2, 2015 , to provide a corporate update and discuss fourth quarter and full year
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
-- Conference Call and Webcast Scheduled for Today at 8:30 a.m. Eastern Time --
View HTML
Toggle Summary Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
SAN DIEGO , Oct. 27, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time ( 5:30 a.m. Pacific Time ) on Monday, November 3, 2014 , to provide a corporate update and discuss third quarter 2014
View HTML
Toggle Summary Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine
WOODCLIFF LAKE, N.J. and SAN DIEGO , Oct. 10, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ ® (lorcaserin HCl) was published in the October issue of
View HTML
Toggle Summary Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium
WOODCLIFF LAKE, N.J. and SAN DIEGO , Sept. 10, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ ® (lorcaserin HCl) CIV will be presented at the American Society of Bariatric Physicians' (ASBP)
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
-- Conference Call and Webcast Scheduled for Today at 8:30 a.m. Eastern Time --
View HTML
Toggle Summary Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
SAN DIEGO , July 25, 2014 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report second quarter 2014 financial results before the NASDAQ Global Select Market opens on Friday, August 1, 2014 .
View HTML
Toggle Summary Lorcaserin HCl Data to be Presented at American Diabetes Association's 74th Scientific Sessions
WOODCLIFF LAKE, N.J. and SAN DIEGO, Calif. , June 9, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ ® (lorcaserin HCl) CIV will be presented at the American Diabetes Association's (ADA)
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2014 Financial Results
-- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time --
View HTML